Next Article in Journal
Extract of Calyces from Physalis peruviana Reduces Insulin Resistance and Oxidative Stress in Streptozotocin-Induced Diabetic Mice
Previous Article in Journal
Evaluation of Nisin-Loaded PLGA Nanoparticles Prepared with Rhamnolipid Cosurfactant against S. aureus Biofilms
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 14
Issue 12
10.3390/pharmaceutics14122757
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Association of Biochemical and Genetic Biomarkers in VEGF Pathway with Depression

by
Fernanda Daniela Dornelas Nunes
1,
Letícia Perticarrara Ferezin
1,
Sherliane Carla Pereira
2,
Fernanda Viana Figaro-Drumond
1,
Lucas Cézar Pinheiro
1,
Itiana Castro Menezes
3,
Cristiane von Werne Baes
3,
Fernanda Borchers Coeli-Lacchini
4,
José Eduardo Tanus-Santos
2,
Mário Francisco Juruena
5 and
Riccardo Lacchini
1,*
1
Department of Psychiatric Nursing and Human Sciences, Ribeirão Preto College of Nursing, University of Sao Paolo, Sao Paulo 14040-902, Brazil
2
Department of Pharmacology, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Sao Paolo 14049-900, Brazil
3
Department of Neuroscience and Behavior, Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo 14049-900, Brazil
4
Blood Center Foundation, Clinics Hospital of the Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Sao Paolo 14051-060, Brazil
5
Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London and South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Monks Orchard Road, Beckenham BR3 3BX, UK
*
Author to whom correspondence should be addressed.
Pharmaceutics 2022, 14(12), 2757; https://doi.org/10.3390/pharmaceutics14122757
Submission received: 25 October 2022 / Revised: 29 November 2022 / Accepted: 5 December 2022 / Published: 9 December 2022
(This article belongs to the Section Pharmacokinetics and Pharmacodynamics)
Browse Figures
Versions Notes

Abstract

:
VEGF is an important neurotrophic and vascular factor involved in mental disorders. The objective of this study was to verify the effect of genetic polymorphisms in the VEGF pathway on the risk for depression, symptom intensity, and suicide attempts. To examine the association between the VEGF pathway and depression, we genotyped polymorphisms and measured the plasma concentrations of VEGF, KDR, and FLT1 proteins. The participants were 160 patients with depression and 114 healthy controls. The questionnaires that assessed the clinical profile of the patients were the MINI-International Neuropsychiatric Interview, GRID-HAMD21, CTQ, BSI, and the number of suicide attempts. Genotyping of participants was performed using the real-time PCR and protein measurements were performed using the enzyme-linked immunosorbent assay (ELISA). VEGF and its inhibitors were reduced in depression. Individuals with depression and displaying the homozygous AA of the rs699947 polymorphism had higher plasma concentrations of VEGF (p-value = 0.006) and were associated with a greater number of suicide attempts (p-value = 0.041). Individuals with depression that were homozygous for the G allele of the FLT1 polymorphism rs7993418 were associated with lower symptom severity (p-value = 0.040). Our results suggest that VEGF pathway polymorphisms are associated with the number of suicide attempts and the severity of depressive symptoms.

1. Introduction

Depression is one of the most common mental disorders, affecting millions of people around the world, increasing incapacity rates among young people and adults [1]. The etiology of depression is complex and has not yet been fully clarified, in addition to being one of the main causes of global mortality for its ability to cause suicide, creating a great burden for patients, family members, and the health system [2]. Suicide is a complex and challenging public health issue. In 2016, 44.965 people died by suicide in the United States, making it the tenth leading cause of death among people aged 10 to 45 years in the country [3]. The discovery of new peripheral biomarkers for depression is of great clinical relevance and has the potential to optimize and qualify the diagnosis, treatment, and prognosis of this mental disorder [4]. Since the first scientific publication recording differences in serum concentrations of brain-derived neurotrophic factor (BDNF) between depressed individuals and healthy controls [5], the hypothesis of imbalance in the neurotrophin system in depression has also been investigated.
Vascular endothelial growth factor (VEGF) is accepted as a multifunctional molecule. VEGF binds to different tyrosine kinase receptors, mainly those related to receptor tyrosine kinase 1 (FLT1) and the kinase insert domain receptor (KDR), with a greater affinity for the latter. It is through these membrane-bound receptors that VEGF performs its potent inducer effect of angiogenesis and vasculogenesis. Interestingly, a soluble form of FLT1 was proposed as an endogenous inhibitor of VEGF since it reduces the VEGF availability to membrane-bound receptors [6,7], and it also has effects on specific areas of the central nervous system (CNS), such as the hippocampus [8]. Neurogenesis has been shown to be stimulated in vitro and in vivo by VEGF [9], in addition to playing a key role in neuronal migration, neuronal survival, and axon orientation [10,11,12]. The inflammatory theory in depression has been widely established in the literature [13]. While under physiological conditions cytokines stimulate neurotrophic factors and neurogenesis [14,15], under excessive and/or prolonged activation these CNS pathways trigger an interconnected set of dysfunctionalities that are increasingly considered relevant to the pathophysiology of depression, such as decreased neurotrophic support and neurogenesis; increased glutamatergic activation, oxidative stress, and induction of apoptosis in astrocytes and oligodendrocytes; and the dysregulation of glial/neuronal interactions and cognitive function [16,17,18,19].
In a context where patients with depression have an exacerbated and harmful inflammatory pattern, it is clear that even the blood–brain barrier (BBB) suffers neurotoxic damage [20] due to this high degree of inflammation. Indeed, a study found that the permeability of the BBB increased because VEGF altered the expression and distribution of tight junction proteins through hypoxia and autoimmune encephalomyelitis [21,22].
In cerebral ischemia, VEGF was able to increase the permeability of the BBB, causing subsequent edema [23,24]. Another interesting protein in this context is s100β, a marker of BBB permeability [25], since s100β is a calcium-binding protein, expressed especially by astrocytes [26], that is practically undetectable in the blood of healthy people [27].
Thus, a possible imbalance of pro-inflammatory cytokines associated with VEGF imbalance and the presence of peripherally circulating s100β may evidence this shared signaling pathway linked to depression, symptom severity, response to antidepressant treatment, and suicide. However, there are controversies. While increased VEGF has been reported in depression [20,28] and this alteration has been reverted by antidepressant treatment [28], other studies failed to show such an association [19,29]. This discrepancy between studies may be explained by significant differences in study populations, age, sex, total number of depressive episodes (i.e., recurrent vs. acute), comorbid disorders, and genetic variability. Further investigation is needed to better understand if this important marker may be used in depression.
In the present study, we aimed to assess whether plasma levels of VEGF, KDR, and FLT1 were associated with depression risk, symptoms intensity, and suicide attempts. Afterwards, we assessed whether genetic polymorphisms of VEGF and its receptors, KDR and FLT1, are associated with depression and severity of symptoms, considering the presence of early life stress in these associations (ELS). Finally, we also assessed whether these polymorphisms associate with plasma concentrations of proteins expressed by their respective genes.

2. Materials and Methods

This is a case–control, observational, cross-sectional study. This study was approved by the Research Ethics Committee of the School of Nursing of Ribeirão Preto and was carried out in accordance with the latest version of the Declaration of Helsinki (CAAE approval number: 04259318.7.0000.5393). The study included 274 participants, including 160 patients with depression and 114 healthy controls. We invited all participants into this study after a brief explanation of the objectives, risks, and benefits, and written informed consent was obtained. The Mental Health Service of the clinic’s hospital and the day hospital unit, which are both at the Faculty of Medicine of Ribeirao Preto (University of São Paulo), performed a patient follow up. The clinical profile of patients is of more complicated cases, since the enrollment was made in tertiary healthcare institutions that received patients with difficulties in controlling symptoms or of suicide risk that were not manageable in primary health care institutions. All patients included here had at least six months of follow up in order to confirm diagnosis and optimize pharmacological treatment. The inclusion criteria were: (a) clinical diagnosis of a depressive episode according to the 5th edition of the Diagnostic and Statistical Manual of Mental Disorder (DSM-5) [30] and (b) age between 18 and 80 years. Exclusion criteria were: significant physical illnesses; steroid use; heavy smoking (over 25 cigarettes a day) or drug/alcohol abuse; pregnancy or lactation; mental disability; psychotic symptoms not considered congruent with major depressive disorder; or depression secondary to organic causes. Control subjects were enrolled from the general population of the University, including its staff, relatives who accompany patients from other clinics for routine examinations (not related to mental disorders), or extension program participants and staff. Inclusion criteria were: (a) self-reported absence of a history of depressive episodes and (b) age between 18 and 80 years. Exclusion criteria for the control group were: detection of any psychiatric or neurological disorder assessed by the Mini International Neuropsychiatric Interview [31,32]; the detection of any major illness after a medical history interview; or detecting a family history of depressive episodes (first-degree relatives).

2.1. Clinical Assessments

The study subjects answered a questionnaire through a face-to-face interview containing questions related to sociodemographic and clinical aspects. Patients underwent psychiatric evaluation where psychometric assessment instruments were applied. The first instrument is the GRID Hamilton Rating Scale for Depression (GRID-HAMD) in its 21-items version (GRID-HAMD21) [33], which is a semi-structured interview. This scale has questions regarding symptoms intensity, with a scale going from 0 to 4 (absent, mild, moderate, severe, and very severe) and questions regarding the frequency of symptoms (absent, occasional, much of the time, and almost all of the time) assessing the last week of the subject’s life. This scale is used frequently both in research and in clinical assessment. The second scale used here was the Childhood Trauma Questionnaire (CTQ) [34,35,36], which assesses a history of early stress, attributing intensity scores for 5 different domains: emotional abuse, physical abuse, sexual abuse, emotional neglect, and physical neglect. The third instrument used here was the Beck Scale for Suicide Ideation (BSI), which assessed the presence of suicidal ideation [37]. BSI is an auto-applicable scale with 21 questions that attribute a maximum score of 44. This scale does not attribute cut points and its score must be considered as a continuous variable. We assessed the number of family- and self-reported suicide attempts by patient. The Mini International Neuropsychiatric Interview questionnaire was used to confirm the diagnosis of depression by the medical team according to the DSM-V criteria [30] and to exclude individuals with mental disorders from the control group. Euthymic mood was defined as a GRID-HAMD21 score ≤ 7. All psychometric scales were applied by expert clinicians (CWWB and MFJ) that frequently discussed the cases and agreed in the clinical assessment.

2.2. Laboratory Measurements

2.2.1. Genotyping

Polymorphisms were chosen using three tier levels of evidence: the first and most significant was evidence showing direct molecular effect of the polymorphism by luciferase assays or protein activity/affinity. An intermediate tier was associations of carriers of the different alleles with different plasma levels of the gene product. The third and less significant tier of evidence was clinical association with disease using the rationale of gain or loss of function of the gene affecting the phenotype risk and how that could translate into depression. Whole-blood samples from all participants were collected using antecubital vein puncture using Vacutainer® (Franklin Lakes, BD, USA) sterile blood tubes containing EDTA anticoagulant and immediately homogenized by inversion. Blood samples were stored at −20 °C until the genetic material was extracted. DNA extraction protocol was based on the salting-out method, as previously described [38]. Genotyping was performed using real-time PCR technique using the StepOne Plus equipment (Applied Biosystems, Waltham, MA, USA). Primers and probes were designed by Applied Biosystems (VEGF rs2010963—C_8311614-10; rs699947—C_8311602-10; KDR rs2071559—C__15869271_10; rs2305948—C__22271999_20; rs1870377—C__11895315_20; FLT1 rs7993418—C__1910654_10). The reaction was performed in 10 μL (5 ng DNA, Taqman Master Mix 1×, Taqman genotyping assay 1×). Fluorescence was quantified and analyzed using the manufacturer’s software.

2.2.2. Protein Measurement

All blood samples were collected from tubes containing heparin for biochemical analysis. After centrifugation, plasma samples were removed, aliquoted, and stored at −80 °C until used. Plasma concentrations of VEGF, KDR, and sFLT1 were measured using enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Abingdon, UK; DuoSet ELISA Human VEGF R2/KDR—Catalog Number DY357; DuoSet ELISA Human VEGF R1/Flt-1—Catalog Number DY321B; and DuoSet ELISA Human VEGF—Catalog Number DY293B) according to the manufacturer’s instructions. Plasma samples were 10-fold diluted for KDR determination and undiluted (concentrated) for VEGF and FLT1 measurement. The reference cut-off values for the plasma levels of tested proteins were previously established through an assay that revealed the limits of detection for each protein. The cutoff points were 7.81 ng/mL for the three proteins VEGF, KDR, and FLT1. Some VEGF and FLT1 results were below cutoff values; therefore, we considered the detection limit value as the final concentration for these samples.

2.3. Statistical Analysis

To describe the results, frequency distribution tables were used in the analysis of categorical variables and measures, such as mean and standard deviation. The groups were compared by chi-square regarding the frequencies of alleles, genotypes, and haplotypes; deviation from Hardy–Weinberg equilibrium; and differences in frequencies of other parameters, such as race, sex, etc. Haplotypes with a frequency of less than 2% were not included in the study. Quantitative variables following normal distribution were analyzed using parametric statistics (Student’s t test and ANOVA with Tukey’s post-test); if not, non-parametric statistics were used (Mann–Whitney U test and Kruskall–Wallis). The effect of genotypes and haplotypes on the scores of the various psychiatric instruments used in this study and/or on the risk for the disease were evaluated using multivariate linear regression or multivariate logistic regression, correcting for independent variables that show an effect in the univariate analysis. We performed this analysis using JMP 5.0.1a software (SAS Institute, Cary, NC, USA). We estimated the haplotypes by combining the studied polymorphisms for the VEGF and KDR genes using the PHASE v2.1 program (https://stephenslab.uchicago.edu/phase/download.html (accessed on 4 December 2022) ). Power analysis calculations were performed using the software Power for Genetic Analyses (Available online: https://dceg.cancer.gov/tools/design/pga (accessed on 4 December 2022)). p < 0.05 was considered statistically significant in all analyses, except in Figures S1–S4, where Bonferroni’s correction was applied. P < 0.0042 was considered significant for Figure S1 (0.05/12 comparisons), and p < 0.0028 was considered significant for Figures S2–S4 (0.05/18 comparisons).

3. Results

3.1. Demographic and Clinical Characteristics

The participants’ clinical, demographic, and environmental characteristics are shown in Table 1. Among them, 114 were part of the control group, of which 79 were women, and 160 were part of the group of patients, of which 127 were female. Most of the sample with depression consisted of females (p-value = 0.028), older subjects (p-value = 0.011), and those with fewer years of education (p-value = 0.0001). The presence of ELS was strongly associated with the group of people with depression when compared with controls (p-value = 0.0001). Table 1 also shows the use of medications by participants with depression and practically all of them use more than one medication. In addition, the GRID-HAMD21 total score was high among these patients (p-value = 0.0001). We also recorded suicide attempts in the group of patients (1.5 ± 2.20), as well as suicidal ideation given by the BSI score (7.2 ± 9.7) (Table 1).

3.2. Association of VEGF Markers with Depression

While Plasma KDR concentrations were significantly lower in patients than in controls (p-value = 0.043, Figure 1A), VEGF and FLT1 were not different (p-value = 0.054 and p-value = 0.052, respectively, Figure 1B,C). A ratio between VEGF and its soluble receptors was calculated, and we found that it was reduced in patients (Figure 1D, p = 0.036). Furthermore, the s100β was also decreased in patients when compared with controls (Figure 1E, p = 0.018). All biochemical analyses were performed with a subset of the whole study sample (51 subjects in control group and 112 in depressive group) due to plasma unavailability. The clinical features of this subset are presented in Table S1.

3.3. Correlations between VEGF and Its Inhibitors, VEGF and S100β, in the Depressive Group

Figure 2 shows the positive correlations between VEGF and its inhibitors, KDR and FLT1, and VEGF and S100β. The one between VEGF and KDR was stronger (Figure 2A, r = 0.54; p-value < 0.0001), while a weaker correlation was found for VEGF and S100β (Figure 2E, r = 0.21; p-value = 0.019).

3.4. VEGF and S100β with GRID-HAM21, BSI, and Number of Suicide Attempts in the Depressive Group

Correlation analyses were performed between the plasma concentrations of each study protein (KDR, FLT1, VEGF, and S100β) and symptom severity, GRID-HAM21, suicidal ideation, BSI, and finally the total number of attempts of suicide. However, no correlation was significant between the biochemical data and the clinical data assessed by these scales (Figure S1). Multivariate models confirmed the lack of association between biochemical data with symptoms, although in some cases, p-values reached near significance (Tables S4–S7).

3.5. Case–Control Genetic Study

When analyzing genetic data, we found no association of the studied SNP with depression, both in direct analysis and multivariate logistic regression models accounting for age, gender, ELS, and education years (Table S2). All genotype frequencies are shown in Table S2. All SNPs were in the Hardy–Weinberg equilibrium. A post hoc power analysis indicated that our number of patients was enough to detect an OR of 1.91 with more than 80% statistical power.

3.6. No Association between Number of Suicide Attempts and Genetic Polymorphisms in the Depressive Group

Figure S2 shows the relationship between genetic polymorphisms and the number of suicide attempts. Figure S2R shows that homozygotes for the A allele of the VEGF polymorphism rs699947 seemed at first to be associated with an increased number of suicide attempts (Figure S2R; p = 0.041); however, the p-value does not resist Bonferroni’s correction. Table 2 shows that after multivariate linear regression the association of the VEGF rs699947 polymorphism with the number of suicide attempts in the recessive model was close to significance (Table 2; p-value = 0.076). Table S3 analyzed suicide as the risk of at least one attempt of suicide. No significant associations were found.

3.7. Rs699947 Contributes to Variations in Plasma VEGF Concentrations in Patients

Homozygous AA carriers for the rs699947 polymorphism had higher plasma concentrations of VEGF in the patient group compared with the other genotype groups (p = 0.002; Table 3).

3.8. Association of FLT1 rs7993418 Polymorphism with Symptom Intensity in Depressives

Individuals that were GG homozygous for the FLT1 polymorphism rs7993418 had higher scores on the GRID-HAMD21 scale, which assesses the severity of depressive symptoms (p-value = 0.003, recessive model; Figure S3L). This result was confirmed by the multivariate linear regression model (p-value = 0.040, Table 2). No associations were found regarding BSI (Figure S4).

3.9. Case-Control Study of Haplotypes: KDR and VEGF

Haplotypes were not associated with disease risk (Table S8) or symptoms (not shown). VEGF haplotypes were significantly associated with plasma VEGF levels in patients (Table S9), as GA haplotype carriers showed increased levels of VEGF when compared with the other haplotypes.

4. Discussion

The main results presented here are reduced plasma levels of KDR, reduced bioavailable VEGF (given by the ratio between VEGF and its receptors), and a reduction in s100β in depressive patients compared with controls. There were also positive correlations between circulating VEGF with its receptors (sFLT and KDR) and s100β. Furthermore, we found a significant association between variant genotypes of rs7993418 polymorphism genotypes and a higher severity of depressive symptoms (GRID-HAM-D21 score). The association of the AA genotype of the rs699947 polymorphism with higher plasma concentrations of VEGF in patients was also found. In the literature, there are still no records of studies that concomitantly evaluated the influence of these genetic polymorphisms on the risk of developing depression and the severity of symptoms. This study will be one of the first to assess the effect of genetic polymorphisms in the VEGF pathway on depression.
Depression is one of the most serious and disabling mental disorders discovered. Worldwide, the incidence of depression increased from 172 million in 1990 to 258 million in 2017, representing an increase of 49.9% [39]. The WHO declared that in 2030 depression would be the disease that would occupy the first place among those that cause greater social, economic, and health system burdens worldwide; furthermore, depression impairs the quality of life of people who manifest it. It is clearly one of the main causes of suicide attempts and death [40,41].
Here, we assessed the genetic and biochemical biomarkers of the vascular endothelial growth factor (VEGF-A) pathway, which is a multifunctional protein with an important neurotrophic capacity induced by hypoxia and pro-inflammatory cytokines [42]. In the clinic, health professionals are faced with difficulties in detecting, diagnosing, and treating depression because of its variable presentations, courses, prognoses, and responses to treatment [43]. Therefore, it is necessary to identify biomarkers that clinically correlate with the signs, symptoms, and severity of these symptoms in order to improve care for people with the disorder. Among these biomarkers are those associated with the theory of inflammation and neurotrophic factors involved in neuroplasticity, such as VEGF, which can help predict susceptibility to the development of depression and response to drug treatment [44].
Control of inflammation can positively impact the overall therapeutic outcome, regardless of whether it is secondary to early trauma, and ensure a more acute stress response, microbiome changes, a genetic diathesis, or an arrangement of these and other factors [45]. Moreover, the increase in VEGF concomitant with the increase in inflammatory cytokines was associated with depression [46]. The signaling of the VEGF pathway involves the activation of two main receptors: fms-related receptor tyrosine kinase 1 FLT-1 (VEGFR-1) and kinase insert domain KDR receptor (VEGFR-2), which participate in neuroprotection and in the formation of new neuronal cells. The soluble form of FLT-1 (soluble fms-like tyrosine kinase-1, sFlt-1) is induced by hypoxia and acts as an anti-angiogenic factor, sequestering free VEGF and attenuating its trophic effects [47]. Changes in VEGF signaling have already been reported in schizophrenia [48] and bipolar affective disorder [49]; however, studies concomitantly addressing VEGF and its receptors have not yet been reported in depression.
Noting that neuroplasticity is affected in depression [50], especially in brain regions such as the hippocampus and prefrontal cortex [50], and in other psychiatric disorders, such as schizophrenia [51] and bipolar affective disorder [52], some studies with animal models [53,54] suggest that the pathophysiology of these disorders is strongly linked to this hypothesis, and there are already studies with drugs that modulate the availability of neurotrophic factors, such as the administration of ketamine, which increased VEGF levels and BDNF in animal model neurons [55]. Another study that evaluated the effect of ketamine in individuals with depression did not observe changes in the plasma levels of BDNF or VEGF [56]. A study that evaluated stress-related exhaustion disorder and VEGF and BDNF levels found that the concentrations of these proteins in the plasma of patients (mean = 39.9 pg/mL; mean = 819.1 pg/mL) were much lower than in healthy controls (mean = 70.0 pg/mL; mean = 2.666 pg/mL) [57]. These values agree with those found in the present study because reduced plasma levels of KDR and decreases in bioavailable VEGF (given by the ratio between VEGF and its receptors) and s100β in depressive patients compared with controls were presented.
Therefore, the interest here in this study led to the investigation of the correlation between VEGF and its receptors and VEGF with S100β, and it was shown that there is a positive correlation between VEGF and FLT1, in addition to the positive correlation of VEGF with S100β [58]. The higher the concentration of plasmatic VEGF available in the blood, the higher the concentrations of sFLT1, KDR, and s100β in this sample. A recent study that evaluated the levels of proteins associated with the neuroplasticity of the cerebrospinal fluid in patients with psychiatric disorders found positive correlations between the scores of a scale that assesses symptom severity in schizophrenia and S100β levels, in addition to a positive correlation between the GRID-HAM21 scores with S100β and KDR concentrations in people with depression [58].
In the post-infarction remodeling process, it was seen that the secretion of VEGF dependent on S100β-RAGE (receptor for advanced glycation end products) by cardiomyocytes induces the proliferation of myofibroblasts [59]. In the case of a cerebrovascular accident (CVA), it is noticed that after the ischemic event, microglia, mast cells, and astrocytes are activated, which increase the permeability of the BBB, facilitating the recruitment of cytokines from the periphery to the brain [60,61]. Activated monocytes and macrophages produce cytokines, free radicals, metalloproteinases, nitric oxide, and many other factors that participate in the reaction through the hypoxemic stimulus [62]. The authors point out that in this context, at lower concentrations, VEGF plays its role in a moderate way by stimulating angiogenesis and preventing neuronal death while decreasing the cytotoxic effect of glutamate, thus increasing cell survival [63,64,65] in addition to effecting its anti-inflammatory action and promoting neuroplasticity, further increasing the migration and proliferation of neuronal precursor cells. However, higher concentrations of VEGF promote strong angiogenesis in the hypoxemic area, which can lead to local edema and a worse prognosis [66].
The genetic polymorphisms studied here show diverse levels of evidence of effects on gene protein levels and associations to diseases. We studied two SNPs in the VEGF gene. The rs699947 (also known as −2578C > A) was shown to reduce the expression of VEGF in peripheral mononuclear cells of AA genotype carriers compared with their counterparts [67]. Here, we found the same result, namely that wild-type CC carriers showed increased levels of VEGF, while CA and AA carriers showed reduced levels of VEGF (Table 3). While this was very exciting, we have not found any association with depression risk, although suicide ideation was very close to significance in the multivariate model (variant genotypes β: +0.45, p = 0.076; Table 2), and it showed a p < 0.05 regarding the number of suicide attempts (AA carriers with almost double the suicide attempts; Figure S2R). Unfortunately, while this result seems very coherent, it must be approached with caution because the clinical association was not statistically significant. In the literature, a study that evaluated the effect of this polymorphism in adults with depression on electroconvulsive therapy (ECT) observed that individuals with the AA genotype did not show an increase in hippocampal volume, which occurred in those with the CC genotype after treatment with ECT [68]. The rs2010963 (−634G > C) was suggested to cause a change in the three-dimensional structure of the VEGF mRNA, which would favor the expression of its long form in C allele carriers [69]. A study that analyzed epistatic interactions between 5-HT1A and VEGF polymorphisms found that interactions between 5-HT1A (rs6295, rs1364043, and rs878567) and VEGF (rs699947, rs833061, and rs2010963) were considered the best model of gene–gene interactions in the association with depressive disorders [70]. Regarding the FLT gene, rs7993418 is located in exon 28 and causes a change in the codon that codes the 1213 tyrosine [71]. It is suggested that this change in the codon could increase VEGF expression in C allele carriers. In the literature, it has been associated with resistance to the antitumor treatment of some types of cancer [71,72]. Interestingly, we found an association between the variant genotypes and the increased symptoms assessed by the GRID-HAMD21 scale. This is surprising because variant alleles should have increased VEGF expression (which was reduced in depressive patients). However, we have not shown an association between VEGF concentrations and changes in GRID-HAMD21 (Supplementary Materials, Figure S1C); therefore, it is possible that VEGF may be more important when assessing the risk of disease, while symptoms intensity may involve other factors. The KDR gene encodes for the second VEGF receptor and we studied three of its polymorphisms. The rs2305948 polymorphism is a non-synonimous SNP in exon 7 that causes the change of aminoacid valine to isoleucine in position 297 of the protein. It was suggested that this aminoacid change could reduce the affinity of VEGF to its receptor [73]. The rs2071559 C allele decreased KDR expression by 68% in vitro [73] when compared with the T allele. Finally, regarding the rs1870377, while there are no functional molecular mechanisms elucidated, A allele carriers had increased plasma levels of KDR [74] when compared with T allele carriers. Furthermore, recently, this polymorphism was associated with schizophrenia, where TT carriers showed a 1.6-fold higher risk in developing schizophrenia when compared with their counterparts [75].
A study that evaluated the association of VEGF and KDR SNPs in patients with severe gliomas showed that VEGFA-2578 C/A and VEGFA-1154G/A increased the risk of severe glioma and that the “CAGT” haplotype of the KDR gene altered the aggressiveness of high-grade glioma and the risk of grade IV tumors [76]. In the present study, among the GA, CC, and GC haplotypes, there was a p-value close to significance for the VEGF CC haplotype with depression; however, this difference was not statistically significant.
Chronic stress has been investigated in affective disorders and especially in depression, as its negative impact on neuroplasticity has been proven by modifying the limbic structures of the CNS [77]. A study that evaluated childhood maltreatment and its impact on the clinical characteristics of major depression in adults observed that these events are common, can be of various types, and are associated with a worse clinical conditions; furthermore, when these types of maltreatment are combined, the individual’s impairment is even bigger [78]. These data are important, since more than half of people with depression in this study suffered some type of early stress and most used more than one medication, scored high on the GRID-HAM-21 scale, and had a family history for depression, which can further enhance the development of the disorder [79].
As limitations of the present study, we should mention the number of included participants, which is robust for biochemical analyses but not for genetic analyses. Nevertheless, we were within our limits to detect genetic associations with OR higher than 1.91 with sufficient power, as calculated by PGA software. With higher numbers of participants, we would be able to detect more subtle associations; therefore, our negative results may be treated with caution. Another limitation that should be cited is the heterogeneous nature of the clinical sample of patients included here. This includes both the pharmacological treatment and subphenotypes of depression. Further studies are needed to confirm the importance of VEGF and its receptors in specific clinical subgroups and treatments.

5. Conclusions

Our data lead us to the conclusion that the circulating levels of target proteins and genetic polymorphisms in the VEGF signaling pathway may be biomarkers for depression and may reflect symptom intensity despite optimized pharmacological treatment.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics14122757/s1, Figure S1: Correlation graph between plasma concentrations of VEGF its inhibitors and VEGF with s100β protein with GRID-HAM21, BSI and number of suicide attempts in depressive group; Figure S2: Direct analysis showing the influence of genotypes on risk of number suicide attempts in patient group; Figure S3: Direct analysis showing the influence of genotypes on GRID-HAMD21 in patient group; Figure S4: Direct analysis showing the influence of genotypes on BSI in patient group; Table S1: Clinical characteristics of control and depressive participants in the biochemical study; Table S2: Multivariate logistic regression showing the distribution of the genotypes between the controls and depressive patients; Table S3: Genotypes distribution of rs2071559, rs2305948, rs1870377, rs7993418, rs2010963 and rs699947 polymorphisms, recessive model, on depressive subjects according to suicide attempts; Table S4: Multivariate linear regression analysis showing GRID-HAMD21 and plasma concentrations of VEGF, KDR, FLT1 and S100ß patients; Table S5: Multivariate linear regression analysis showing BSI and plasma concentrations of VEGF, KDR, FLT1 and S100ß patients; Table S6: Multivariate linear regression analysis showing BSI and plasma concentrations of S100ß and ratio patients; Table S7: Multivariate linear regression analysis showing number of suicide attempts and plasma concentrations of VEGF, KDR, FLT1 and S100ß patients; Table S8: Multivariate logistics regression analysis showing influence of haplotypes on control and depressive groups; Table S9: Multivariate linear regression analysis showing influence of haplotypes on plasma concentration of VEGF patients.

Author Contributions

Conceptualization, J.E.T.-S., M.F.J. and R.L.; data curation, R.L.; formal analysis, F.D.D.N., L.P.F., L.C.P. and F.B.C.-L.; investigation, F.D.D.N., S.C.P. and C.v.W.B.; methodology, F.D.D.N., L.P.F., S.C.P., F.V.F.-D., I.C.M. and C.v.W.B.; project administration, R.L.; resources, R.L.; supervision, M.F.J. and R.L.; writing—original draft, F.D.D.N.; writing—review and editing, L.P.F., S.C.P., F.V.F.-D., L.C.P., I.C.M., C.v.W.B., F.B.C.-L., J.E.T.-S., M.F.J. and R.L. All authors have read and agreed to the published version of the manuscript.

Funding

This work has been supported by the following Brazilian research agencies: the São Paulo Research Foundation (FAPESP—grant #2018/18312-2), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES—finance code 01), and the National Council for Scientific and Technological Development (CNPq—grant #440579/2014-7 and 302898/2020-4).

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Ethics Committee of Ribeirao Preto College of Nursing (protocol code CAAE 04259318.7.0000.5393, approved on 13 December 2018).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Murray, C.J.; Vos, T.; Lozano, R.; Naghavi, M.; Flaxman, A.D.; Michaud, C.; Ezzati, M.; Shibuya, K.; Salomon, J.A.; Abdalla, S.; et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380, 2197–2223. [Google Scholar] [CrossRef] [PubMed]
  2. Barnett, R. Depression. Lancet 2019, 393, 2113. [Google Scholar] [CrossRef] [PubMed]
  3. Leading Causes of Death Reports. 2016. Available online: https://wisqars.cdc.gov/fatal-leading (accessed on 22 March 2022).
  4. Xie, T.; Stathopoulou, M.G.; de Andrés, F.; Siest, G.; Murray, H.; Martin, M.; Cobaleda, J.; Delgado, A.; Lamont, J.; Peñas-LIedó, E.; et al. VEGF-related polymorphisms identified by GWAS and risk for major depression. Transl. Psychiatry 2017, 7, e1055. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Karege, F.; Perret, G.; Bondolfi, G.; Schwald, M.; Bertschy, G.; Aubry, J.M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002, 109, 143–148. [Google Scholar] [CrossRef]
  6. Hoeben, A.; Landuyt, B.; Highley, M.S.; Wildiers, H.; Van Oosterom, A.T.; De Bruijn, E.A. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev. 2004, 56, 549–580. [Google Scholar] [CrossRef] [Green Version]
  7. Pitsillou, E.; Bresnehan, S.M.; Kagarakis, E.A.; Wijoyo, S.J.; Liang, J.; Hung, A.; Karagiannis, T.C. The cellular and molecular basis of major depressive disorder: Towards a unified model for understanding clinical depression. Mol. Biol. Rep. 2020, 47, 753–770. [Google Scholar] [CrossRef]
  8. Cao, L.; Jiao, X.; Zuzga, D.S.; Liu, Y.; Fong, D.M.; Young, D.; During, M.J. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat. Genet. 2004, 36, 827–835. [Google Scholar] [CrossRef]
  9. Jin, K.; Zhu, Y.; Sun, Y.; Mao, X.O.; Xie, L.; Greenberg, D.A. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2002, 99, 11946–11950. [Google Scholar] [CrossRef] [Green Version]
  10. Mackenzie, F.; Ruhrberg, C. Diverse roles for VEGF-A in the nervous system. Development 2012, 139, 1371–1380. [Google Scholar] [CrossRef] [Green Version]
  11. Storkebaum, E.; Lambrechts, D.; Carmeliet, P. VEGF: Once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004, 26, 943–954. [Google Scholar] [CrossRef]
  12. Greenberg, D.A.; Jin, K. Experiencing VEGF. Nat. Genet. 2004, 36, 792–793. [Google Scholar] [CrossRef] [PubMed]
  13. Goldsmith, D.R.; Rapaport, M.H.; Miller, B.J. A meta-analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression. Mol. Psychiatry 2016, 21, 1696–1709. [Google Scholar] [CrossRef] [PubMed]
  14. Janelidze, S.; Suchankova, P.; Ekman, A.; Erhardt, S.; Sellgren, C.; Samuelsson, M.; Westrin, A.; Minthon, L.; Hansson, O.; Träskman-Bendz, L.; et al. Low IL-8 is associated with anxiety in suicidal patients: Genetic variation and decreased protein levels. Acta Psychiatr. Scand. 2015, 131, 269–278. [Google Scholar] [CrossRef] [PubMed]
  15. Janelidze, S.; Ventorp, F.; Erhardt, S.; Hansson, O.; Minthon, L.; Flax, J.; Samuelsson, M.; Traskman-Bendz, L.; Brundin, L. Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters. Psychoneuroendocrinology 2013, 38, 853–862. [Google Scholar] [CrossRef]
  16. Schmidt, H.D.; Shelton, R.C.; Duman, R.S. Functional biomarkers of depression: Diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 2011, 36, 2375–2394. [Google Scholar] [CrossRef] [Green Version]
  17. Jonsdottir, I.H.; Hägg, D.A.; Glise, K.; Ekman, R. Monocyte chemotactic protein-1 (MCP-1) and growth factors called into question as markers of prolonged psychosocial stress. PLoS ONE 2009, 4, e7659. [Google Scholar] [CrossRef] [Green Version]
  18. Juengst, S.B.; Kumar, R.G.; Failla, M.D.; Goyal, A.; Wagner, A.K. Acute inflammatory biomarker profiles predict depression risk following moderate to severe traumatic brain injury. J. Head Trauma Rehabil. 2015, 30, 207–218. [Google Scholar] [CrossRef]
  19. Kahl, K.G.; Bens, S.; Ziegler, K.; Rudolf, S.; Kordon, A.; Dibbelt, L.; Schweiger, U. Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology 2009, 34, 353–357. [Google Scholar] [CrossRef]
  20. Huang, X.; Hussain, B.; Chang, J. Peripheral inflammation and blood-brain barrier disruption: Effects and mechanisms. CNS Neurosci. Ther. 2021, 27, 36–47. [Google Scholar] [CrossRef]
  21. Schoch, H.J.; Fischer, S.; Marti, H.H. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain A J. Neurol. 2002, 125, 2549–2557. [Google Scholar] [CrossRef]
  22. Argaw, A.T.; Gurfein, B.T.; Zhang, Y.; Zameer, A.; John, G.R. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc. Natl. Acad. Sci. USA 2009, 106, 1977–1982. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Engelhardt, S.; Patkar, S.; Ogunshola, O.O. Cell-specific blood-brain barrier regulation in health and disease: A focus on hypoxia. Br. J. Pharmacol. 2014, 171, 1210–1230. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Zhang, Z.G.; Zhang, L.; Jiang, Q.; Zhang, R.; Davies, K.; Powers, C.; Bruggen, N.; Chopp, M. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J. Clin. Investig. 2000, 106, 829–838. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Donato, R.; Sorci, G.; Riuzzi, F.; Arcuri, C.; Bianchi, R.; Brozzi, F.; Tubaro, C.; Giambanco, I. S100B’s double life: Intracellular regulator and extracellular signal. Biochim. Biophys. Acta 2009, 1793, 1008–1022. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Schroeter, M.L.; Abdul-Khaliq, H.; Krebs, M.; Diefenbacher, A.; Blasig, I.E. Serum markers support disease-specific glial pathology in major depression. J. Affect Disord. 2008, 111, 271–280. [Google Scholar] [CrossRef] [PubMed]
  27. Kanner, A.A.; Marchi, N.; Fazio, V.; Mayberg, M.R.; Koltz, M.T.; Siomin, V.; Stevens, G.H.; Masaryk, T.; Aumayr, B.; Ayumar, B.; et al. Serum S100beta: A noninvasive marker of blood-brain barrier function and brain lesions. Cancer 2003, 97, 2806–2813. [Google Scholar] [CrossRef] [Green Version]
  28. Iga, J.; Ueno, S.; Yamauchi, K.; Numata, S.; Tayoshi-Shibuya, S.; Kinouchi, S.; Nakataki, M.; Song, H.; Hokoishi, K.; Tanabe, H.; et al. Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31, 658–663. [Google Scholar] [CrossRef]
  29. Ventriglia, M.; Zanardini, R.; Pedrini, L.; Placentino, A.; Nielsen, M.G.; Gennarelli, M.; Bocchio-Chiavetto, L. VEGF serum levels in depressed patients during SSRI antidepressant treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33, 146–149. [Google Scholar] [CrossRef]
  30. APA, A.P.A. Manual Diagnóstico e Estatístico de Transtornos Mentais: DSM-5, 5th ed.; Artmed: Porto Alegre, Brazil, 2014; Volume 5, p. 948. [Google Scholar]
  31. Sheehan, D.V.; Lecrubier, Y.; Sheehan, K.H.; Amorim, P.; Janavs, J.; Weiller, E.; Hergueta, T.; Baker, R.; Dunbar, G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59 (Suppl. S20), 22–33, quiz 34–57. [Google Scholar]
  32. Amorim, P. Mini International Neuropsychiatric Interview (MINI): Validation of a short structured diagnostic psychiatric interview. Rev. Bras. Psiquiatr. 2000, 22, 106–115. [Google Scholar] [CrossRef] [Green Version]
  33. Henrique-Araújo, R.; Osório, F.L.; Gonçalves Ribeiro, M.; Soares Monteiro, I.; Williams, J.B.; Kalali, A.; Alexandre Crippa, J.; Oliveira, I.R. Transcultural Adaptation of GRID Hamilton Rating Scale For Depression (GRID-HAMD) to Brazilian Portuguese and Evaluation of the Impact of Training Upon Inter-Rater Reliability. Innov. Clin. Neurosci. 2014, 11, 10–18. [Google Scholar] [PubMed]
  34. Bernstein, D.P.; Fink, L.; Handelsman, L.; Foote, J.; Lovejoy, M.; Wenzel, K.; Sapareto, E.; Ruggiero, J. Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am. J. Psychiatry 1994, 151, 1132–1136. [Google Scholar] [CrossRef]
  35. Bernstein, D.P.; Stein, J.A.; Newcomb, M.D.; Walker, E.; Pogge, D.; Ahluvalia, T.; Stokes, J.; Handelsman, L.; Medrano, M.; Desmond, D.; et al. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse Negl. 2003, 27, 169–190. [Google Scholar] [CrossRef] [PubMed]
  36. Grassi-Oliveira, R.; Stein, L.M.; Pezzi, J.C. Translation and content validation of the Childhood Trauma Questionnaire into Portuguese language. Rev. Saude Publica 2006, 40, 249–255. [Google Scholar] [CrossRef] [PubMed]
  37. Beck, A.T.; Ward, C.H.; Mendelson, M.; Mock, J.; Erbaugh, J. An inventory for measuring depression. Arch. Gen. Psychiatry 1961, 4, 561–571. [Google Scholar] [CrossRef] [Green Version]
  38. Vasconcellos, V.; Lacchini, R.; Jacob-Ferreira, A.; Sales, M.; Ferreira-Sae, M.; Schreiber, R.; Nadruz, W.; Tanus-Santos, J. Endothelial nitric oxide synthase haplotypes associated with hypertension do not predispose to cardiac hypertrophy. DNA Cell Biol. 2010, 29, 171–176. [Google Scholar] [CrossRef]
  39. Liu, Q.; He, H.; Yang, J.; Feng, X.; Zhao, F.; Lyu, J. Changes in the global burden of depression from 1990 to 2017: Findings from the Global Burden of Disease study. J. Psychiatr. Res. 2020, 126, 134–140. [Google Scholar] [CrossRef]
  40. Ribeiro, J.D.; Huang, X.; Fox, K.R.; Franklin, J.C. Depression and hopelessness as risk factors for suicide ideation, attempts and death: Meta-analysis of longitudinal studies. Br. J. Psychiatry 2018, 212, 279–286. [Google Scholar] [CrossRef]
  41. World Health Organization (WHO). The Global Burden of Disease: 2004 Update; World Health Organization (WHO): Geneva, Switzerland, 2008. [Google Scholar]
  42. Ruiz de Almodovar, C.; Lambrechts, D.; Mazzone, M.; Carmeliet, P. Role and therapeutic potential of VEGF in the nervous system. Physiol. Rev. 2009, 89, 607–648. [Google Scholar] [CrossRef]
  43. MacQueen, G.; Santaguida, P.; Keshavarz, H.; Jaworska, N.; Levine, M.; Beyene, J.; Raina, P. Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults. Can. J. Psychiatry 2017, 62, 11–23. [Google Scholar] [CrossRef]
  44. Mora, C.; Zonca, V.; Riva, M.A.; Cattaneo, A. Blood biomarkers and treatment response in major depression. Expert Rev. Mol. Diagn. 2018, 18, 513–529. [Google Scholar] [CrossRef] [PubMed]
  45. Beurel, E.; Toups, M.; Nemeroff, C.B. The Bidirectional Relationship of Depression and Inflammation: Double Trouble. Neuron 2020, 107, 234–256. [Google Scholar] [CrossRef] [PubMed]
  46. He, Y.; Li, W.; Wang, Y.; Tian, Y.; Chen, X.; Wu, Z.; Lan, T.; Li, Y.; Bai, M.; Liu, J.; et al. Major depression accompanied with inflammation and multiple cytokines alterations: Evidences from clinical patients to macaca fascicularis and LPS-induced depressive mice model. J. Affect Disord. 2020, 271, 262–271. [Google Scholar] [CrossRef] [PubMed]
  47. Nevo, O.; Lee, D.K.; Caniggia, I. Attenuation of VEGFR-2 expression by sFlt-1 and low oxygen in human placenta. PLoS ONE 2013, 8, e81176. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Lee, B.H.; Hong, J.P.; Hwang, J.A.; Ham, B.J.; Na, K.S.; Kim, W.J.; Trigo, J.; Kim, Y.K. Alterations in plasma vascular endothelial growth factor levels in patients with schizophrenia before and after treatment. Psychiatry Res. 2015, 228, 95–99. [Google Scholar] [CrossRef]
  49. van den Ameele, S.; Coppens, V.; Schuermans, J.; De Boer, P.; Timmers, M.; Fransen, E.; Sabbe, B.; Morrens, M. Neurotrophic and inflammatory markers in bipolar disorder: A prospective study. Psychoneuroendocrinology 2017, 84, 143–150. [Google Scholar] [CrossRef]
  50. Levy, M.J.F.; Boulle, F.; Steinbusch, H.W.; van den Hove, D.L.A.; Kenis, G.; Lanfumey, L. Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression. Psychopharmacology 2018, 235, 2195–2220. [Google Scholar] [CrossRef] [Green Version]
  51. De Picker, L.J.; Morrens, M.; Chance, S.A.; Boche, D. Microglia and Brain Plasticity in Acute Psychosis and Schizophrenia Illness Course: A Meta-Review. Front. Psychiatry 2017, 8, 238. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Machado-Vieira, R.; Soeiro-De-Souza, M.G.; Richards, E.M.; Teixeira, A.L.; Zarate, C.A. Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: Developing treatments using an integrated translational approach. World J. Biol. Psychiatry 2014, 15, 84–95. [Google Scholar] [CrossRef] [Green Version]
  53. Monday, H.R.; Younts, T.J.; Castillo, P.E. Long-Term Plasticity of Neurotransmitter Release: Emerging Mechanisms and Contributions to Brain Function and Disease. Annu. Rev. Neurosci. 2018, 41, 299–322. [Google Scholar] [CrossRef]
  54. Hagihara, H.; Takao, K.; Walton, N.M.; Matsumoto, M.; Miyakawa, T. Immature dentate gyrus: An endophenotype of neuropsychiatric disorders. Neural Plast. 2013, 2013, 318596. [Google Scholar] [CrossRef] [PubMed]
  55. Deyama, S.; Bang, E.; Kato, T.; Li, X.Y.; Duman, R.S. Neurotrophic and Antidepressant Actions of Brain-Derived Neurotrophic Factor Require Vascular Endothelial Growth Factor. Biol. Psychiatry 2019, 86, 143–152. [Google Scholar] [CrossRef] [PubMed]
  56. Medeiros, G.C.; Greenstein, D.; Kadriu, B.; Yuan, P.; Park, L.T.; Gould, T.D.; Zarate, C.A. Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor. J. Affect. Disord. 2021, 280, 136–139. [Google Scholar] [CrossRef] [PubMed]
  57. Sjörs Dahlman, A.; Blennow, K.; Zetterberg, H.; Glise, K.; Jonsdottir, I.H. Growth factors and neurotrophins in patients with stress-related exhaustion disorder. Psychoneuroendocrinology 2019, 109, 104415. [Google Scholar] [CrossRef]
  58. Hidese, S.; Hattori, K.; Sasayama, D.; Tsumagari, T.; Miyakawa, T.; Matsumura, R.; Yokota, Y.; Ishida, I.; Matsuo, J.; Yoshida, S.; et al. Cerebrospinal fluid neuroplasticity-associated protein levels in patients with psychiatric disorders: A multiplex immunoassay study. Transl. Psychiatry 2020, 10, 161. [Google Scholar] [CrossRef]
  59. Tsoporis, J.N.; Izhar, S.; Proteau, G.; Slaughter, G.; Parker, T.G. S100B-RAGE dependent VEGF secretion by cardiac myocytes induces myofibroblast proliferation. J. Mol. Cell Cardiol. 2012, 52, 464–473. [Google Scholar] [CrossRef]
  60. Lindsberg, P.J.; Strbian, D.; Karjalainen-Lindsberg, M.-L. Mast Cells as Early Responders in the Regulation of Acute Blood–Brain Barrier Changes after Cerebral Ischemia and Hemorrhage. J. Cereb. Blood Flow Metab. 2010, 30, 689–702. [Google Scholar] [CrossRef] [Green Version]
  61. Lasek-Bal, A.; Jedrzejowska-Szypulka, H.; Student, S.; Warsz-Wianecka, A.; Zareba, K.; Puz, P.; Bal, W.; Pawletko, K.; Lewin-Kowalik, J. The importance of selected markers of inflammation and blood-brain barrier damage for short-term ischemic stroke prognosis. J. Physiol. Pharmacol. 2019, 70. [Google Scholar] [CrossRef]
  62. McKittrick, C.M.; Lawrence, C.E.; Carswell, H.V.O. Mast cells promote blood brain barrier breakdown and neutrophil infiltration in a mouse model of focal cerebral ischemia. J. Cereb Blood Flow Metab. 2015, 35, 638–647. [Google Scholar] [CrossRef] [Green Version]
  63. Lee, J.W.; Bae, S.H.; Jeong, J.W.; Kim, S.H.; Kim, K.W. Hypoxia-inducible factor (HIF-1)alpha: Its protein stability and biological functions. Exp. Mol. Med. 2004, 36, 1–12. [Google Scholar] [CrossRef] [Green Version]
  64. Sun, Y.; Jin, K.; Xie, L.; Childs, J.; Mao, X.O.; Logvinova, A.; Greenberg, D.A. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J. Clin. Investig. 2003, 111, 1843–1851. [Google Scholar] [CrossRef] [PubMed]
  65. Sun, F.Y.; Guo, X. Molecular and cellular mechanisms of neuroprotection by vascular endothelial growth factor. J. Neurosci. Res. 2005, 79, 180–184. [Google Scholar] [CrossRef] [PubMed]
  66. Manoonkitiwongsa, P.S.; Schultz, R.L.; McCreery, D.B.; Whitter, E.F.; Lyden, P.D. Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis. J. Cereb Blood Flow Metab. 2004, 24, 693–702. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  67. Shahbazi, M.; Fryer, A.A.; Pravica, V.; Brogan, I.J.; Ramsay, H.M.; Hutchinson, I.V.; Harden, P.N. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J. Am. Soc. Nephrol. 2002, 13, 260–264. [Google Scholar] [CrossRef]
  68. Van Den Bossche, M.J.A.; Emsell, L.; Dols, A.; Vansteelandt, K.; De Winter, F.L.; Van den Stock, J.; Sienaert, P.; Stek, M.L.; Bouckaert, F.; Vandenbulcke, M. Hippocampal volume change following ECT is mediated by rs699947 in the promotor region of VEGF. Transl. Psychiatry 2019, 9, 191. [Google Scholar] [CrossRef] [Green Version]
  69. Lambrechts, D.; Storkebaum, E.; Morimoto, M.; Del-Favero, J.; Desmet, F.; Marklund, S.L.; Wyns, S.; Thijs, V.; Andersson, J.; van Marion, I.; et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 2003, 34, 383–394. [Google Scholar] [CrossRef] [Green Version]
  70. Han, D.; Qiao, Z.; Qi, D.; Yang, J.; Yang, X.; Ma, J.; Wang, L.; Song, X.; Zhao, E.; Zhang, J.; et al. Epistatic Interaction Between 5-HT1A and Vascular Endothelial Growth Factor Gene Polymorphisms in the Northern Chinese Han Population With Major Depressive Disorder. Front. Psychiatry 2019, 10, 218. [Google Scholar] [CrossRef]
  71. Lambrechts, D.; Claes, B.; Delmar, P.; Reumers, J.; Mazzone, M.; Yesilyurt, B.T.; Devlieger, R.; Verslype, C.; Tejpar, S.; Wildiers, H.; et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: An analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 2012, 13, 724–733. [Google Scholar] [CrossRef]
  72. Beuselinck, B.; Jean-Baptiste, J.; Schöffski, P.; Couchy, G.; Meiller, C.; Rolland, F.; Allory, Y.; Joniau, S.; Verkarre, V.; Elaidi, R.; et al. Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib. BJU Int. 2016, 118, 890–901. [Google Scholar] [CrossRef] [Green Version]
  73. Wang, Y.; Zheng, Y.; Zhang, W.; Yu, H.; Lou, K.; Zhang, Y.; Qin, Q.; Zhao, B.; Yang, Y.; Hui, R. Polymorphisms of KDR gene are associated with coronary heart disease. J. Am. Coll. Cardiol. 2007, 50, 760–767. [Google Scholar] [CrossRef]
  74. Al Awaida, W.; Ahmed, A.A.; Hamza, A.A.; Amber, K.I.; Al-Ameer, H.J.; Jarrar, Y.; Fatima, G.; Maslat, A.O.; Gushchina, Y.; Al Bawareed, O.; et al. Association of KDR rs1870377 genotype with clopidogrel resistance in patients with post percutaneous coronary intervention. Heliyon 2021, 7, e06251. [Google Scholar] [CrossRef] [PubMed]
  75. Saoud, H.; Aflouk, Y.; Ben Afia, A.; Gaha, L.; Bel Hadj Jrad, B. Association of VEGF-A and KDR polymorphisms with the development of schizophrenia. Hum. Immunol. 2022, 83, 528–537. [Google Scholar] [CrossRef] [PubMed]
  76. Vasconcelos, V.C.A.; Lourenc, G.J.; Brito, A.B.C.; Vasconcelos, V.L.; Maldaun, M.V.C.; Tedeschi, H.; Marie, S.K.N.; Shinjo, S.M.O.; Lima, C.S.P. Associations of VEGFA and KDR single-nucleotide polymorphisms and increased risk and aggressiveness of high-grade gliomas. Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med. 2019, 41, 1–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Nowacka, M.; Obuchowicz, E. BDNF and VEGF in the pathogenesis of stress-induced affective diseases: An insight from experimental studies. Pharmacol. Rep. 2013, 65, 535–546. [Google Scholar] [CrossRef] [PubMed]
  78. Medeiros, G.C.; Prueitt, W.L.; Minhajuddin, A.; Patel, S.S.; Czysz, A.H.; Furman, J.L.; Mason, B.L.; Rush, A.J.; Jha, M.K.; Trivedi, M.H. Childhood maltreatment and impact on clinical features of major depression in adults. Psychiatry Res. 2020, 293, 113412. [Google Scholar] [CrossRef]
  79. Brent, D.A.; Brunwasser, S.M.; Hollon, S.D.; Weersing, V.R.; Clarke, G.N.; Dickerson, J.F.; Beardslee, W.R.; Gladstone, T.R.; Porta, G.; Lynch, F.L.; et al. Effect of a Cognitive-Behavioral Prevention Program on Depression 6 Years After Implementation Among At-Risk Adolescents: A Randomized Clinical Trial. JAMA Psychiatry 2015, 72, 1110–1118. [Google Scholar] [CrossRef]
Pharmaceutics 14 02757 g001 550
Figure 1. Distribution KDR, VEGF, FLT1, and s100β plasma concentrations between VEGF and its inhibitors in control and patient groups. Legend: (A) KDR plasma concentration; (B) FLT1 plasma concentration; (C) VEGF plasma concentration; (D) ratio between VEGF and its inhibitors plasma concentration; (E) s100β plasma concentration. All plasma concentrations were expressed as mean and standard deviation. Mann–Whitney test. * p < 0.05 was considered statistically significant.
Figure 1. Distribution KDR, VEGF, FLT1, and s100β plasma concentrations between VEGF and its inhibitors in control and patient groups. Legend: (A) KDR plasma concentration; (B) FLT1 plasma concentration; (C) VEGF plasma concentration; (D) ratio between VEGF and its inhibitors plasma concentration; (E) s100β plasma concentration. All plasma concentrations were expressed as mean and standard deviation. Mann–Whitney test. * p < 0.05 was considered statistically significant.
Pharmaceutics 14 02757 g001
Pharmaceutics 14 02757 g002 550
Figure 2. Correlation graph between plasma concentrations of VEGF with its inhibitors and VEGF with s100β protein in depressive group. Legend: Spearman’s test was used for non-parametric analysis and Pearson’s test was used for parametric analysis. * p < 0.05 was considered statistically significant. (A) correlation analysis between KDR and VEGF; (B) correlation analysis between FLT1 and VEGF; (C) correlation analysis between s100β and KDR; (D) correlation analysis between s100β and FLT1; (E) correlation analysis between s100β and VEGF.
Figure 2. Correlation graph between plasma concentrations of VEGF with its inhibitors and VEGF with s100β protein in depressive group. Legend: Spearman’s test was used for non-parametric analysis and Pearson’s test was used for parametric analysis. * p < 0.05 was considered statistically significant. (A) correlation analysis between KDR and VEGF; (B) correlation analysis between FLT1 and VEGF; (C) correlation analysis between s100β and KDR; (D) correlation analysis between s100β and FLT1; (E) correlation analysis between s100β and VEGF.
Pharmaceutics 14 02757 g002
Table
Table 1. Clinical characteristics of control and depressive participants.
Table 1. Clinical characteristics of control and depressive participants.
Clinical FeatureControl (n = 114)Depressive
(n = 160)		p
Age (years)37.9 ± 16.341.7 ± 12.10.011 *
Gender (female) n (%)79 (70%)127 (79.3%)0.028 *
Body Mass Index (kg/m²)27.1 ± 5.128.7 ± 8.30.113
Education (years)15.1 ± 3.710.7 ± 4.8<0.001 *
Early-life Stress (yes) n (%)9 (8.6%)83 (52.0%)<0.001 *
Ethnicity (whites)69 (63.3%)91 (57.0%)0.619
Current smokers7 (6.4%)20 (13.5%)0.064
Alcohol consumption6 (5.5%)2 (1.4%)0.078
Illegal drugs abuse (yes)0 (0%)1 (0%)1.000
Familiar history of depression (yes) n (%)-88 (59%)-
Depression pharmacological treatment n (%)
SSRI or SNRI or atypical antidepressants -110 (68.7%)-
Anxiolytics -73 (45.3%)-
Tricyclic antidepressants -29 (18%)-
Antipsychotics -52 (32.5%)-
Mood stabilizers -50 (31.2%)-
Thyroid hormone -20 (12.4%)
Suicidal attempts
GRID-HAMD21		-
0.55 ± 0.92		1.5 ± 2.20
18.0 ± 9.8		-
<0.001 *
BSI-7.2 ± 9.7-
* Statistically significant (p < 0.05). Selective serotonin reuptake inhibitors (SSRIs); serotonin norepinephrine reuptake inhibitors (SNRIs).
Table
Table 2. Multivariate linear regression analysis showing the influence of genotypes and recessive model on GRID-HAMD21 and BSI scores and number of suicide attempts.
Table 2. Multivariate linear regression analysis showing the influence of genotypes and recessive model on GRID-HAMD21 and BSI scores and number of suicide attempts.
Dependent Variables
GRID-HAMD21 ScoreBSI ScoreNumber of Suicide Attempts
Independent variablesR²: 0.25RMSE: 8.91R²: 0.25RMSE: 8.80R²: 0.28RMSE: 1.77
βPβPβP
Age (years)−0.060.378−0.220.003−0.030.027
Gender (female)0.010.9971.350.1770.060.729
Education (years)−0.460.011 *−0.470.009−0.120.001
Early-life stress (yes)1.560.0522.280.0050.420.011
Pharmacological treatment
SSRI or SNRI or atypical antidepressants0.720.4160.750.4050.270.146
Anxiolytics2.730.001 *0.840.318−0.020.863
Tricyclic antidepressants 0.400.6911.020.3060.550.007
Antipsychotics−0.180.8341.200.1790.080.645
Mood stabilizers 0.260.7600.510.5680.200.265
Genetic Markers
KDR rs2071559
GG−0.800.927−0.200.8170.050.750
AG + AA0.800.9270.200.817−0.050.750
KDR rs2305948
TT3.510.2120.260.923−0.330.548
CT + CC−3.510.212−0.260.9230.330.548
KDR rs1870377
AA−1.290.522−2.040.305−0.140.740
TA + TT1.290.5222.040.3050.140.740
FLT1 rs7993418
GG.−2.730.040 *−1.490.2520.170.517
AG + AA2.730.040 *1.490.252−0.170.517
VEGF rs2010963
CC0.510.6450.210.856−0.020.900
GC + GG−0.510.645−0.210.8560.020.900
VEGF rs699947
AA−0.730.551−0.110.926−0.450.076
CA + CC0.730.5510.110.9260.450.076
SSRI: Serotonin selective reuptake inhibitor; SNRI: serotonin and noradrenaline selective reuptake inhibitor; R²: the proportion of the variability of the mean that is explained by the current model; RMSE: root mean square error. * p < 0.05 was considered statistically significant.
Table
Table 3. Multivariate linear regression analysis showing the influence of genotypes on VEGF plasma concentrations and additive model in the depressive group.
Table 3. Multivariate linear regression analysis showing the influence of genotypes on VEGF plasma concentrations and additive model in the depressive group.
Dependent Variables
VEGF (pg/mL)
Independent variablesR²: 0.19RMSE: 126
βP
Age (years)−1.720.163
Gender (female)6.710.707
Education (years)3.210.253
Early-life stress (yes)2.800.827
Pharmacological treatment
SSRI or SNRI or atypical antidepressants −11.310.430
Anxiolytics−3.810.781
Tricyclic antidepressants 9.220.568
Antipsychotics−10.530.448
Mood stabilizers −6.840.627
Genetic Markers
VEGF rs2010963
GG−10.960.675
GC3.090.860
CC2827.970.742
Global p−Value: 0.915
VEGF rs699947
CC97.050.002 *
CA−48.980.012 *
AA−48.060.056
Global p−Value: 0.006 *
SSRI: Serotonin selective reuptake inhibitor; SNRI: serotonin and noradrenaline selective reuptake inhibitor; R²: the proportion of the variability of the mean that is explained by the current model; RMSE: root mean square error. * p < 0.05 was considered statistically significant.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Nunes, F.D.D.; Ferezin, L.P.; Pereira, S.C.; Figaro-Drumond, F.V.; Pinheiro, L.C.; Menezes, I.C.; Baes, C.v.W.; Coeli-Lacchini, F.B.; Tanus-Santos, J.E.; Juruena, M.F.; et al. The Association of Biochemical and Genetic Biomarkers in VEGF Pathway with Depression. Pharmaceutics 2022, 14, 2757. https://doi.org/10.3390/pharmaceutics14122757

AMA Style

Nunes FDD, Ferezin LP, Pereira SC, Figaro-Drumond FV, Pinheiro LC, Menezes IC, Baes CvW, Coeli-Lacchini FB, Tanus-Santos JE, Juruena MF, et al. The Association of Biochemical and Genetic Biomarkers in VEGF Pathway with Depression. Pharmaceutics. 2022; 14(12):2757. https://doi.org/10.3390/pharmaceutics14122757

Chicago/Turabian Style

Nunes, Fernanda Daniela Dornelas, Letícia Perticarrara Ferezin, Sherliane Carla Pereira, Fernanda Viana Figaro-Drumond, Lucas Cézar Pinheiro, Itiana Castro Menezes, Cristiane von Werne Baes, Fernanda Borchers Coeli-Lacchini, José Eduardo Tanus-Santos, Mário Francisco Juruena, and et al. 2022. "The Association of Biochemical and Genetic Biomarkers in VEGF Pathway with Depression" Pharmaceutics 14, no. 12: 2757. https://doi.org/10.3390/pharmaceutics14122757

APA Style

Nunes, F. D. D., Ferezin, L. P., Pereira, S. C., Figaro-Drumond, F. V., Pinheiro, L. C., Menezes, I. C., Baes, C. v. W., Coeli-Lacchini, F. B., Tanus-Santos, J. E., Juruena, M. F., & Lacchini, R. (2022). The Association of Biochemical and Genetic Biomarkers in VEGF Pathway with Depression. Pharmaceutics, 14(12), 2757. https://doi.org/10.3390/pharmaceutics14122757

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop